The B subunit of Shiga toxin and the Shiga-like toxins (SLTs) mediates receptor binding, cytotoxic specificity, and extracellular localization of the holotoxin. While the functional receptor for Shiga toxin, SLT type I (SLT-I), and SLT-II is the glycolipid designated Gb3, SLT-II variant (SLT-IIv) may use a different glycolipid receptor. To identify the domains responsible for receptor binding, localization in Escherichia coli, and recognition by neutralizing monoclonal antibodies, oligonucleotide-directed site-specific mutagenesis was used to alter amino acid residues in the B subunits of Shiga toxin and SLT-IIv. Mutagenesis of a well-conserved hydrophilic region near the amino terminus of the Shiga toxin B subunit rendered the molecule nontoxic but did not affect immunoreactivity or holotoxin assembly. In addition, elimination of one cysteine residue, as well as truncation of the B polypeptide by 5 amino acids, caused a total loss of activity. Changing a glutamate to a glutamine at the carboxyl terminus of the Shiga toxin B subunit resulted in the loss of receptor binding and immunoreactivity. However, the corresponding mutation in the SLT-IIv B subunit (glutamine to glutamate) did not reduce the levels of cytotoxicity but did affect extracellular localization of the holotoxin in E. coli.
The B subunit of Shiga toxin and the Shiga-like toxins (SLTs) mediates receptor binding, cytotoxic specificity, and extracellular localization of the holotoxin. While the functional receptor for Shiga toxin, SLT type I (SLT-I), and SLT-II is the glycolipid designated Gb3, SLT-II variant (SLT-IIv) may use a different glycolipid receptor. To identify the domains responsible for receptor binding, localization in Escherichia coli, and recognition by neutralizing monoclonal antibodies, oligonucleotide-directed site-specific mutagenesis was used to alter amino acid residues in the B subunits of Shiga toxin and SLT-IIv. Mutagenesis of a well-conserved hydrophilic region near the amino terminus of the Shiga toxin B subunit rendered the molecule nontoxic but did not affect immunoreactivity or holotoxin assembly. In addition, elimination of one cysteine residue, as well as truncation of the B polypeptide by 5 amino acids, caused a total loss of activity. Changing a glutamate to a glutamine at the carboxyl terminus of the Shiga toxin B subunit resulted in the loss of receptor binding and immunoreactivity. However, the corresponding mutation in the SLT-IIv B subunit (glutamine to glutamate) did not reduce the levels of cytotoxicity but did affect extracellular localization of the holotoxin in E. coli.
Shiga toxin, which is produced by Shigella dysenteriae type 1, and the Shiga-like toxin (SLTs), which are produced by enterohemorrhagic strains of Escherichia coli, possess similar biological and biochemical properties (18) . Nucleotide sequence analysis revealed that Shiga toxin and SLT type I (SLT-I) are essentially identical (22) while SLT-II is 55% homologous to both (8) . SLT-II variant (SLT-IIv), which is produced by edema disease-causing strains of E. coli, is antigenically related to SLT-II but differs from the other members of the Shiga toxin family with respect to cytotoxic specificity (15) . While Shiga toxin, SLT-I, and SLT-II are predominantly cell associated in E. coli and are equally cytotoxic for HeLa and Vero cells, SLT-IIv is predominantly extracellular and is markedly more cytotoxic for Vero cells. All members of the Shiga toxin family are bipartite molecules composed of an enzymatic A subunit, which is a 28S rRNA N-glycosidase (3, 20) , and multiple copies of a binding (B) subunit. The functional receptor for the B subunits of Shiga toxin, SLT-I, and SLT-II is the glycolipid receptor designated Gb3 (13, 25 Studies with hybrid toxins composed of the A and B subunits of Shiga toxin, SLT-I, SLT-II, and SLT-IIv demonstrated that the B moiety dictates cytotoxic specificity and extracellular localization in E. coli (26) . Comparison of the deduced sequences of Shiga toxin/SLT-I (22) , and SLT-II (8) with that of SLT-IIv (27) (19) . E. coli MC4100 has been described by Casadaban (1 Oligonuceotide-directed site-specific mutagenesis. The double-oligonucleotide primer method of Zoller and Smith (28) and was used to introduce point mutations in stx B and slt-IIv B. Oligonucleotides designed to introduce point mutations were synthesized on the basis of the sequences of stx (22) and slt-IIv (27) with a model 380A DNA synthesizer (Applied Biosystems, Inc., Foster City, Calif.). The singlestranded templates used for mutagenesis were M13mpl8 containing a 1.8-kb HindIII-EcoRI fragment carrying stx B (Fig. 1A ), M13mpl9 containing a 1.5-kb EcoRI-PstI fragment carrying upstream slt-IIvB sequences (Fig. 1B) , or M13mpl8 containing a 0.5-kb PstI-EcoRI fragment carrying downstream slt-Ilv B sequences (Fig. 1C ). All mutations were confirmed by DNA sequence analysis. The mutagenic oligonucleotides used in this study are described in Table 1 .
Construction of operons. Mutagenized stx B carried by a 1.8-kb HindIII-EcoRI fragment was isolated from the replicative form of M13 following site-directed mutagenesis. This fragment was simultaneously ligated with a 0.75-kb BglII-HindIII fragment carrying upstream stx A sequences into BamHI-and EcoRI-digested pBR329 to construct the intact stx operon (Fig. 1A) . To construct double mutations at distant residues, the HindIII-EcoRI fragment cloned in M13mpl8 was subjected to two rounds of site-directed mutagenesis before isolation and construction of the stx operon.
The mutagenized slt-IIv operon was constructed with either a 1.5-kb EcoRI-PstI fragment carrying the upstream sequences of slt-IIv B (mutations N17D and 152K; Fig. 1B) or a 0.5-kb PstI-EcoRI fragment carrying the downstream sequences of slt-IIv B (mutation Q64E; Fig. 1C ). These restriction fragments isolated from the replicative form of the M13 vector after site-directed mutagenesis were ligated with fragments containing the remainder of the slt-IIv operon into pBR329 (Fig. 1B and C) . To construct the slt-IIv double mutants N17D,Q64E and 152K,Q64E, the EcoRIPstI fragment carrying mutagenized upstream slt-IIv B sequences was ligated to the PstI-EcoRI fragment carrying mutagenized downstream slt-IIv B sequences into EcoRIdigested pBR329. All manipulations of high-level toxinproducing clones were conducted under BL3+ EK1 containment (4) .
Colony blot assay. A colony blot enzyme-linked immunosorbent assay (ELISA) was used to assess the immunoreactivity of mutagenized Shiga toxin B subunits expressed by E. coli transformed with the recombinant plasmids described above. Toxin released from bacterial colonies by treatment with polymyxin B (2 mg/ml for 1 h at 37°C) was bound to a nitrocellulose membrane, and an ELISA was performed as previously described (23) . Three Shiga toxin B subunitspecific monoclonal antibodies designated 13C4, 19G8, and 16E6 (23) were used in the colony blot assays.
Microcytotoxicity assay. The levels of Vero and HeLa cell toxicity for wild-type and mutant Shiga toxin and SLT-IIv were assessed by using the microcytotoxicity assay of Gentry and Dalrymple (5) . Both extracellular (supernatant) and cell-associated (cytoplasmic and periplasmic) fractions were collected for assay as previously described (16 to bind the glycolipid receptor Gb3 was assessed in an ELISA with the receptor analog Gal-Gal-bovine serum albumin as previously described (27) . A 1:3,500 dilution of ascites fluid containing the Shiga toxin A subunit-specific monoclonal antibody 4F7.3 (kindly provided by J. E. Brown) was used to detect bound toxin (6) .
Minicell analysis. To determine if B subunit with the D16H,D17H double mutation could associate with A subunit to form Shiga holotoxin, "S-labeled polypeptides were immunoprecipitated from the periplasm of a minicell-producing strain of E. coli as described by Meagher et al. (17) .
Total 35S-labeled polypeptides were extracted with polymyxin B, and Shiga toxin was immunoprecipitated (10) with the B subunit-specific monoclonal antibody 13C4 followed by goat antimouse immunoglobulin G as described by Strockbine et al. (23) . The immunoprecipitated extracts were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography to identify labeled A and B subunit polypeptides (12) .
RESULTS AND DISCUSSION
It has been proposed that a hydrophilic sequence between residues 10 to 20 in the Shiga toxin B subunit is an antigenic domain of the polypeptide (21) . Evidence that this sequence does contribute to antigenicity was obtained by Harari et al. (7), who prepared neutralizing antibodies against synthetic peptides corresponding to this region of the Shiga toxin B subunit. This region is well conserved in the B subunits of Shiga toxin, SLT-I, SLT-II, and SLT-IIv (8, 22, 27) (Fig. 2) . Two double and three single amino acid substitutions designed to reduce the hydrophilicity of this region were induced at aspartate residues 16, 17, and 18 of the Shiga toxin B subunit. Only the double mutation of aspartates 16 and 17 to histidines (D16H,D17H [ Table 2 ]) had a significant effect on activity. This double mutation caused the total loss of cytotoxic activity on HeLa and Vero cells and eliminated receptor analog binding. However, the mutated polypeptide was fully immunoreactive in the colony blot ELISA with the three monoclonal antibodies (13C4, 16E6, and 19G8) that were specific for the native Shiga toxin B subunit ( Table 2 ). The aspartate residues at positions 16 and 17 could be part of the receptor binding site. Alternatively, they could be required to maintain the functional conformation of a receptor- 15 20 binding site located elsewhere in the B subunit. Both the A and B subunits were immunoprecipitated by using monoclonal antibody 13C4 from periplasmic extracts of E. coli minicells encoding the mutated stx operon (data not shown). This observation established that the D16H,D17H double mutation did not prevent holotoxin assembly.
The remaining single and double mutations induced in the Shiga toxin B subunit (K53I; D18N,K531; G25S,D26G; and S38P) were based on a comparison with the SLT-IIv B subunit sequence (Fig. 2) . Toxin mutated at lysine 53 (K531 and K53I,D18N) was reduced 10-fold in cytotoxicity and expressed approximately 20% of wild-type receptor analog binding (Table 2 ). In addition, B polypeptide mutated at lysine 53 was not immunoreactive with the monoclonal antibody 19G8 but was recognized by 13C4 and 16E6. The remaining mutations, G25S,D26G and S38P, did not have a significant effect on total cytotoxic levels, immunoreactivity, or receptor analog binding. Our results suggest that lysine 53 is part of the epitope recognized by monoclonal antibody 19G8. No data concerning the structure of the epitopes recognized by monoclonal antibodies 13C4 or 16E6 are available.
Amber termination mutations were introduced at codons corresponding to the following four residues of the mature Shiga toxin B subunit: tryptophan 34, cysteine 57, asparagine 59, and glutamate 65 (Table 3) . When the stx operon with any of these four amber mutations was expressed in E. coli MC4100, which lacks suppressor activity, no toxin was detected in tests for HeLa and Vero cell toxicity, receptor analog binding assays, or colony blot assays with any of the three B subunit-specific monoclonal antibodies (data not shown). Because the carboxyl-terminal-most amber mutation was at codon 65, these results indicate that truncating the B subunit by 5 amino acids at the carboxyl terminus inactivates Shiga toxin.
When the stx operons containing amber mutations at codon 34 or 59 were expressed in E. coli HB101 or LE392, toxicity was partially to fully restored (Table 3 ). The level of activity expressed was influenced by the efficiency of chain propagation from the suppressor tRNA encoded by the host (9) , with the double suppressor host LE392 expressing 2 to 3 orders of magnitude more cytotoxicity than the single suppressor host HB101 (Table 3) . Because the receptor analog assay required the expression of at least 106 CD50/ml, no (14) .
Nomenclature is given in footnote b of (Table  3) . Therefore, both lysine 53 and asparagine 59 contribute to the epitope defined by monoclonal antibody 19G8. In a separate study, Surewicz et al. (24) used fluorescence spectroscopy to demonstrate that tryptophan 34 is at or very near the Gb3 receptor-binding domain. However, replacement of this tryptophan with a glutamine or a tyrosine did not prevent binding to the receptor analog ( Table 3 ), indicating that this tryptophan residue was not directly involved in receptor recognition.
The nonsense mutation at codon 57 was not phenotypically suppressed in E. coli HB101 or LE392 (Table 3) . Because there are only two cysteine residues in the Shiga toxin B subunit (Fig. 2) , replacement of cysteine 57 with a glutamine or tyrosine eliminated the single intrachain disulfide bond. Also, the nonsense mutation at codon 65 was not suppressed. Expression of this mutation in HB101 replaced glutamate 65 with a glutamine, the residue at the corresponding position in B subunit of SLT-IIv (Fig. 2) . The glutamate 65-to-glutamine change in the Shiga toxin B subunit rendered the toxin inactive in all assays (Table 3) , while the reciprocal change in the SLT-IIv B subunit (Q64E) altered extracellular localization of the toxin in E. coli without drastically affecting Vero cell toxicity (Table 4) . These results indicate that while the carboxyl terminus of SLT-IIv B was important for release of holotoxin from the periplasm, the carboxyl terminus of the Shiga toxin B subunit was a domain important for the structural integrity and perhaps assembly of the holotoxin. Alternatively, the Shiga toxin B subunit with the glutamate 65 mutation may have been an unstable polypeptide that was degraded by the cell.
Three amino acid residues in the SLT-IIv B subunit were mutated to the corresponding residue in the Shiga toxin B subunit (Fig. 2) . Because neither a monoclonal antibody nor a receptor analog ELISA was available for SLT-IIv, the only assay used to analyze mutant toxin was that measuring the VOL. 172, 1990 FUNCTIONAL ANALYSIS OF SHIGA TOXIN AND SLT-II VARIANT 657 ability to kill Vero and HeLa cells. As with native toxin, the mutated forms of SLT-IIv were cytotoxic for Vero cells only, with no detectable activity for HeLa cells. Compared with native SLT-IIv expressed by pDLW5.3, the glutamineto-glutamate mutation at residue 64 had no effect on the cell-associated levels of cytotoxicity (104 CD5Jml) but reduced the extracellular levels of activity 1,000-fold (from 105 to 102 CD5dml [ Table 4 ]. SLT-IIv with the double mutations N17D,Q64E and I52K,Q64E, which included the glutamine 64-to-glutamate change, was present in cell-associated fractions but was not detectable in culture supernatants ( Table  4 ). The SLT-IIv B subunit is a relatively basic molecule with an isoelectric point of 10.2 (23) . The pI was reduced by replacing the glutamine with a glutamate, and this change may have affected the localization of SLT-IIv by disrupting ionic interactions with the E. coli cell envelope. The remaining mutations induced in SLT-IIv B, N17D and 152K, caused 10-fold and 100-fold reductions in the levels of cytotoxicity, respectively, with no effect on toxin localization.
While no single amino acid could be identified as the B subunit receptor-binding moiety, mutagenesis of the hydrophiic region near the amino terminus of the Shiga toxin B subunit eliminated receptor binding without affecting holotoxin assembly. Furthermore, the carboxyl terminus of Shiga toxin may be important for biological activity and holotoxin assembly, while the carboxyl terminus of SLT-IIv is involved in determining the extracellular localization of that toxin in E. coli. Multiple residues distantly separated in the primary structure of the Shiga toxin and SLT-IIv B subunits may be required for receptor recognition. It is not known whether the receptor-binding site lies within a single B polypeptide or is formed by the interaction of adjacent B polypeptides.
